Medtronic (MDT) Offering Possible 12.87% Return Over the Next 28 Calendar Days

Medtronic's most recent trend suggests a bullish bias. One trading opportunity on Medtronic is a Bull Put Spread using a strike $95.00 short put and a strike $90.00 long put offers a potential 12.87% return on risk over the next 28 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $95.00 by expiration. The full premium credit of $0.57 would be kept by the premium seller. The risk of $4.43 would be incurred if the stock dropped below the $90.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Medtronic is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Medtronic is bullish.

The RSI indicator is above 80 which suggests that the stock is in overbought territory.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Medtronic

10 ‘Buy-and-Hold’ Stocks to Own Forever
Wed, 19 Jun 2019 12:30:26 +0000
Editor's note: This story was previously published in February 2019. It has since been updated and republished.Investing to "buy and hold" is trickier than it looks. The increasing pace of technological change means even the most successful, dominant companies have to continually adapt to keep up. Industries like energy, real estate and even consumer products are facing potentially significant long-term changes going forward. In any era, amassing a collection of retirement stocks simply by buying the best companies and holding them for years can be a risky endeavor.General Motors (NYSE:GM) was a classic "widows and orphans" stock until last decade, when GM wound up going bankrupt. United States Steel (NYSE:X) once was a pillar of corporate America and a buy-and-hold stock. GM shares basically haven't moved in a quarter of a century. Polaroid and Eastman Kodak were once blue-chip stocks. Both went bankrupt as cameras changed from film to digital.InvestorPlace – Stock Market News, Stock Advice & Trading TipsBut there still are stocks to buy and hold out there that can last forever, while offering dividend income along the way. * 7 Value Stocks to Buy for the Second Half Here are ten such retirement stocks to buy and hold forever.Source: Shutterstock Bank of America (BAC)Dividend Yield: 2.1%It might seem strange to open the list with Bank of America (NYSE:BAC). After all, we're only a bit more than a decade on from the financial crisis. During that crisis, BofA acquisition Countrywide Financial blew up in spectacular fashion, after pioneering many of the risky tactics that led to the bubble and subsequent bust.But this is a different BofA.Net consumer charge-offs hit a decade-long low last year. Its performance on credit metrics is strong. Government regulations have been criticized as slowing growth — but they've undoubtedly lowered risk as well, even if observers might argue that a better balance is needed.No less than Warren Buffett is now BofA's largest shareholder, through his Berkshire Hathaway Inc. (NYSE:BRK.A, NYSE:BRK.B). And the Oracle of Omaha is fond of saying that his favorite holding period is "forever."That seems likely true for BAC stock as well.Source: Mustafa Khayat Via Flickr Diageo (DEO)Dividend Yield: 2%Change has come to the alcohol industry, with the number of breweries exploding worldwide and new distilleries popping up as well. The brands owned by Diageo (NYSE:DEO) are well-positioned to adapt to shifting tastes.Diageo owns classic brands like Johnnie Walker whisky, Tanqueray gin, Smirnoff vodka, and Harp and Guinness beer, among many others. What most have in common is a timeless quality and worldwide brand recognition. As a result, while beverage giants like Coca-Cola (NYSE:KO) and Anheuser Busch InBev (NYSE:BUD) have struggled with earnings growth, Diageo grew net income by 13.5% in fiscal 2018 and expects consistent growth going forward. * 7 Value Stocks to Buy for the Second Half Yet with a trailing multiple of 26.5, and with a dividend yield of 2%, Diageo stock isn't all that dearly valued. Long-term investors would do well to own DEO and perhaps use the dividends to buy a bottle or two of fine whisky.Source: U.S. Embassy Kyiv Ukraine via Flickr (Modified) Medtronic (MDT)Dividend Yield: 2%In this day and age, the U.S. healthcare market in particular seems potentially volatile. Concerns about increased spending and political battles over the Affordable Care Act create more questions than answers.But even with that uncertainty, Medtronic (NYSE:MDT) isn't going anywhere. The company's devices are an integral part of modern medicine, ranging from pacemakers to stents to bone grafts to imaging systems.Even the risks involved in the sector look priced into MDT. Medtronic's days of double-digit annual growth may well be behind it, but it's not finished increasing earnings or dividends. MDT stock likely isn't finished rising, either.Source: Shutterstock NextEra Energy (NEE)Dividend Yield: 2.4%Utility stocks are among the most common safe, buy-and-hold stocks. NextEra Energy (NYSE:NEE) is now the largest electric utility in the U.S. by market capitalization. That might actually be the only problem with NEE stock.NextEra shares gained 18% year-to-date, and trades just off record highs. Potential valuation concerns aside, NextEra looks like a winner. It serves customers in the southern Florida region, still one of the nation's fastest-growing areas. A 22.6 forward P/E multiple is high for the space but not outlandishly so. And a 2.4% dividend yield provides income along the way. * 7 Dividend Stocks to Buy as the Trade War Reignites Investors looking for value in the space might look for a smaller play like cheaper Dominion Energy (NYSE:D). But it's usually worth paying for quality, and NextEra Energy looks like one of the best utility stocks out there.Source: Blue Genie via Flickr McCormick & CompanyDividend Yield: 1.5%McCormick & Company (NYSE:MKC) is another quality company whose valuation might spook some investors. But MKC stock very rarely is offered cheaply.The company's market leadership in spices and seasonings provides both an impressive moat and protection against economic downturns. MKC stock did dip after the company acquired French's mustard and Frank's RedHot sauce from Reckitt Benckiser (OTCMKTS:RBGLY) at a price that looked a bit high to many investors. But MKC has recovered those gains and then some.Top-line growth for McCormick likely isn't going to be explosive, but it will be steady. The same has been true of MKC stock, which has returned an average of 13% a year over the past decade, including dividends.With continuous cost-cutting initiatives, the contribution from the acquired brands and organic growth (and growth in organic products), MKC still should be able to provide double-digit annual returns going forward as well.Source: Shutterstock Allstate CorpDividend Yield: 2%Allstate Corp (NYSE:ALL) long has used the tagline, "You're in good hands," and it's true for Allstate investors as well. ALL stock has almost quadrupled from late-2011 lows. And there could be more upside to come.After all, Allstate isn't particularly expensive, trading at a 14 P/E. * 7 Value Stocks to Buy for the Second Half Once any short-term worries subside, ALL should resume its march upward.Source: Shutterstock International Flavors & Fragrances (IFF)Dividend Yield: 2%International Flavors & Fragrances (NYSE:IFF) is a company most consumers encounter every day without knowing it and many investors aren't exactly hip to it, either.As its name suggests, the company develops flavors & fragrances across 13 categories, including cosmetics, perfumes, beverages and sweet flavors. Sales and earnings have increased consistently and so has IFF's share price. At a 53 P/E, IFF does look a bit pricey. But, as with McCormick and other stocks on this list, investors should pay for quality.IFF's hidden, but key role, in so many industries, gives it a great deal of protection against both competition and macro factors. Acquisitions and a growing cosmetic additive business both provide room for growth.Consumers may not know IFF, but investors should.Source: Shutterstock Lamb WestonDividend Yield: 1.4%Lamb Weston (NYSE:LW) was spun off from Conagra Brands (NYSE:CAG) last year. Lamb Weston is the No. 1 potato producer in the United States. In fact, it manufactures the well-known fries at McDonald's (NYSE:MCD), among other restaurant chains.Lamb Weston also has a consumer business (including a small segment that manufactures frozen vegetables), while serving restaurants of all sizes. Health concerns might seem a long-term headwind against the business, but growth has been steady for years, and margins continue to improve.LW is targeting international markets for growth, as French fries have much more limited penetration, while international audiences generally are intrigued by Americanized products.Despite growth and leading market share, LW stock isn't particularly cheap, trading at about 19 times next year's earnings. The company did pick up a fair amount of debt in the CAG spinoff. But it's paying that debt down, which should lower interest expense and boost cash flow going forward. * 7 Value Stocks to Buy for the Second Half With many similar stocks trading at much higher multiples, LW seems to have room for upside. And international growth should offset any health-related concerns in the U.S., should they arise. America's love affair with French fries isn't going to suddenly end, and that should ensure years of stability for Lamb Weston at least.Source: Shutterstock Fortune Brands (FBHS)Dividend Yield: 1.6%Investors are commonly advised to diversify their portfolio. Fortune Brands Home & Security (NYSE:FBHS) has done just that. The company operates in four segments: Cabinets, Plumbing, Doors, and Security. Among its well-known brands are Moen in plumbing, and MasterLock in security.FBHS is more of a cyclical stock than most on this list, and the company no doubt has benefited from the steady, if slow, housing recovery in the U.S. But the company's products also generate relatively stable replacement demand, and a 1.6% dividend yield provides modest, but growing, income.Fortune Brands has been an impressive company since its founding and a solid stock since its 2011 IPO. There may be a bit more volatility here, but that's a worthwhile price to pay for long-term investors. There's enough value in Fortune Brands to ride out any market jitters.Source: Shutterstock Republic ServicesDividend Yield: 1.74%Republic Services (NYSE:RSG) is a bit smaller and likely a lot less well-known than rival Waste Management (NYSE:WM). But in this case, that's not necessarily a bad thing.Republic Services has outgrown its larger competitor in both sales and earnings over the past five years. RSG stock has modestly outperformed WM over the same period as well. Investors appear to believe that will continue, as Republic Services is valued a bit higher than Waste Management, at least based on forward earnings multiples.Both RSG and WM are solid long-term plays. Contracted revenue and steady demand should support both companies for years to come. There's room for further acquisitions in a relatively fragmented space. Republic Services gets the nod here due to slightly better growth and more room for margin improvement. * 7 Value Stocks to Buy for the Second Half But investors looking for safe, stable growth can't go wrong with either RSG or WM.As of this writing, Vince Martin was long MKC. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Value Stocks to Buy for the Second Half * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer * 6 Chip Stocks Staring At Big Headwinds in 2019 Compare Brokers The post 10 'Buy-and-Hold' Stocks to Own Forever appeared first on InvestorPlace.

Locust Wood Capital Advisers’ Return, AUM, and Holdings
Wed, 19 Jun 2019 05:29:43 +0000
Back in 2002 Stephen J. Errico, a Wall Street investor, who now has more than 30 years of professional investing experience, launched his own NYC-based hedge fund, Locust Wood Capital Advisers. Aside from being the fund's founder he is also its CIO and Controling Principal. Previously, Mr. Errico worked at Morgan Stanley as a portfolio […]

See what the IHS Markit Score report has to say about Medtronic PLC.
Tue, 18 Jun 2019 12:06:34 +0000
Medtronic PLC NYSE:MDTView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for MDT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MDT. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding MDT are favorable, with net inflows of $9.39 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

3 Stocks To Buy Ahead of Fed Cuts, Says Goldman Sachs
Mon, 17 Jun 2019 12:32:53 +0000
All eyes are on the US Federal Reserve right now. On Wednesday, the Fed will reveal whether it decides to slash interest rates or keep them steady at 2.25% – 2.50%. Ahead of the announcement, the general consensus is that the Fed will keep rates steady but set the groundwork for cuts when it next meets in July. “The markets are set up for a cut in July, and if they don’t get it, financial conditions will tighten” Carl Tannenbaum, chief economist at Northern Trust, told Reuters.So how should investors prepare their portfolios going forward? Goldman Sachs has some advice. “If the Fed does cut rates, the S&P 500 usually rallies afterward, with health care and consumer staples outperforming and information technology consistently lagging,” Goldman's chief U.S. equity strategist David Kostin said. The “communication services sector has generated the best relative returns and hit rate of outperformance during the subsequent 3 months (+4 pp, 100%), but has underperformed over a 12-month horizon.”Here we take a closer look at three stocks that fit into these two categories, with 2 healthcare stocks and 1 consumer staples stock. What’s more, all three of these stocks show a ‘Strong Buy’ Street consensus. That’s based on all ratings received over the last three months. Let’s take a closer look at why analysts are so bullish on these stocks now: 1\. Boston Scientific (BSX)Boston Scientific manufactures medical devices used in interventional medical specialties, including everything from needles to pacemakers. Shares are up 14% year-to-date, and over 80% on a three-year basis. Right now, the company is gearing up for its investor day on June 26. This is the first event since 2017- and expectations are high that BSX met or exceeded all of the 2017 and 2018 financial targets. Needham analyst Mike Matson is confident that BSX can sustain high single digit growth over the next few years, and expects it to target organic revenue growth of 7-9% from 2019 to 2022 at the event. “Given BSX’s strong fundamentals (durable high single digit revenue growth, diversified product portfolio, margin expansion potential, etc.), we believe there is potential for upside to consensus estimates and additional multiple expansion and we reiterate our Strong Buy rating” writes Matson. He reiterated his BSX ‘Buy’ rating on June 14 with a $46 price target (14% upside potential). As we can see here the stock has received 9 recent buy ratings and 1 hold rating:View BSX Price Target & Analyst Ratings Detail 2\. Medtronic (MDT)Ireland-based Medtronic is one of the world’s largest medical device makers. Although the company manufactures a wide range of products, most of the hype right now is centered on the MazorX robotic platform. Medtronic snapped up Mazor Robotics for $1.7 billion late last year, and the two companies have now developed the MazorX Stealth Edition robotic guidance platform. The power of the platform is a preoperative planning suite with 3D analytics and tools, which allows surgeons to optimize the surgical process in advance. “Part of MDT’s revenue acceleration thesis depends on the success of MazorX in driving spine share gains” writes Evercore ISI analyst Vijay Kumar. He recently reiterated his Medtronic Buy rating with a $108 price target. “We think MDT’s view of ‘several hundred bps of share gains’ in spine remains a credible thesis given early trends we are seeing. Extrapolating these to general surgery (~80% systems placed for committed implant / consumable volume) lends further credence to why we think robotic surgery could be a big deal for MDT” writes Kumar. The analyst concludes: “We think MDT is the perfect stock for a choppy environment, and should be a core holding given this revenue reacceleration thesis.” That’s alongside Wells Fargo analyst Larry Biegelsen upgrading Medtronic from Hold to Buy with a $110 price target. The analyst comments "We believe MDT is an accelerating growth story trading at a steep discount to its peers."Overall 7 analysts have published buy ratings on MDT in the last three months, with just 2 analysts staying sidelined.View MDT Price Target & Analyst Ratings Detail 3\. Tyson Foods (TSN)While many investors are pouring money into Beyond Foods, it’s also worth taking a closer look at Tyson Foods. This is the world's second largest processor and marketer of chicken, beef, and pork. However the company has also recently branched out into plant-based meat alternatives, including chicken nuggets and patties. Shares have rocketed with a 53% gain so far year-to-date. Boosting prices further was a rating upgrade from Argus Research’s John Staszak. He has a $92 price target on TSN (12% upside potential).Staszak cited a “growing demand for proteins" and notes that Tyson's beef division is experiencing "especially strong demand". Plus the company is working hard to increase prepared foods sales to satisfy the "steady demand and strong margins." And to top of it, Tyson trades at a multiple of just 12.8-times forward earnings, which is below the average large-cap food processor multiple of 18.4-times. It’s also easily towards the low end of Tyson’s own historical 9- to 19-times range. The stock boasts 7 recent bullish calls, with only 1 analyst publishing a Sell rating (Pivotal Research's Timothy Ramey). View TSN Price Target & Analyst Ratings Detail Discover stock ideas from the Street’s best performing analysts here

Why This Method Of Replacing A Faulty Heart Valve Is Gaining Steam
Fri, 14 Jun 2019 20:29:35 +0000
A nonsurgical method of heart-valve replacement, dubbed TAVR, is gaining steam in the U.S. — propping up medical technology companies Edwards and Medtronic, an analyst said Friday.

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.